Inclusion Criteria:

          -  Histological confirmed diagnosis of high risk non-muscle invasive transitional cell
             carcinoma (TCC) of the urothelium of the urinary bladder (tumors of mixed
             transitional/non-transitional cell histology are allowed, but TCC must be the
             predominant histology)

          -  Complete resection of all Ta/T1 papillary disease (including participants with
             concurrent CIS), with most recent TURBT occurring within 12 weeks prior to
             randomization. A second TURBT must have been performed if indicated according to the
             current locally applicable guidelines, ie, American Urological Association, European
             Association of Urology

        Exclusion Criteria:

          -  Evidence of muscle-invasive, locally advanced or metastatic urothelial cancer or
             concurrent extravesical, non-muscle invasive TCC of the urothelium

          -  Intravesical BCG therapy within 2 years prior to randomization. Prior intravesical
             chemotherapy for NMIBC is allowed

          -  Prior immunotherapy with anti PD-1, anti PD-L1, anti PD-L2, or anti cytotoxic
             T-lymphocyte-associated antigen-4 (CTLA-4) antibody

          -  Prior treatment with immunostimulatory agents including interleukin (IL)-2, IL-15,
             interferon (INF)

          -  Prior radiation therapy to the bladder